Fusion Protein Between Short Form Rod-Derived Cone Viability Factor and a Hydrophilic Peptide
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/US2017/056030, filed Oct 11, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,946,063 | Fusion Protein Between Short Form Rod-Derived Cone Viability Factor and a Hydrophilic Peptide In force · High confidence | Pharma Cinq, LLC | In force | High confidence | ||
| US 12,076,367 | Fusion Protein Between Short Form Rod-Derived Cone Viability Factor and a Hydrophilic Peptide In force · High confidence | Pharma Cinq, LLC | In force | High confidence | ||
| Application 18/785,213 | Fusion Protein Between Short Form Rod-Derived Cone Viability Factor and a Hydrophilic Peptide Pending Not granted | Pharma Cinq, LLC | Pending | Not granted | not computed |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Pharma Cinq, LLC.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.